Anzeige
Meldung des Tages: Antimon vor dem Durchbruch? 50 Mio. Bewertung trifft Milliarden-Fantasie!

Kuros Biosciences Aktie News

Aktie
WKN:  A2ALS5 ISIN:  CH0325814116 US-Symbol:  CSBTF Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Schweiz
25,50 CHF
-0,54 CHF
-2,07%
27,913 € 23.02.26
Depot/Watchlist
Marktkapitalisierung *
1,17 Mrd. €
Streubesitz
50,08%
KGV
-221,50
Index-Zuordnung
-

Kuros Biosciences News

13.01.26 - GlobeNewswire
Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences
Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the ...
02.12.25 - GlobeNewswire
Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-​center clinical trial in foot and ankle fusion Schlieren (Zürich), ...
26.11.25 - GlobeNewswire
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
Kuros Biosciences to present at the Piper Sandler 37 th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the ...
16.10.25 - GlobeNewswire
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-​over-year increase ...
30.09.25 - GlobeNewswire
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or ...
18.09.25 - GlobeNewswire
Kuros statement on media inquiry concerning former Board member
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros statement on media inquiry concerning former Board member Schlieren (Zurich), Switzerland, September ...
04.09.25 - GlobeNewswire
Kuros Biosciences announces changes in the Board of Directors
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, ...
14.08.25 - GlobeNewswire
Kuros Biosciences Reports First Half of 2025 Results
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by ...
05.08.25 - GlobeNewswire
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Schlieren (Zürich), ...
13.05.25 - GlobeNewswire
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros ...
15.04.25 - GlobeNewswire
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next ...
15.04.25 - GlobeNewswire
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & ...
11.03.25 - GlobeNewswire
Kuros Biosciences grows sales to CHF 75.6 million for 2024
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales ...

Newssuche

Videos

newspaper
18.02.26 -4,22%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »